Saito T, Shigemitsu Y, Kinoshita T, Shimoda K, Abe T, Nakamura A, Chikuba K, Kobayashi M
Department of Surgery I, Oita Medical University, Japan.
Oncology. 1993 Jul-Aug;50(4):293-7. doi: 10.1159/000227198.
Between 1986 and 1991, 35 patients with esophageal cancer (TNM stages II-IV) underwent transthoracic esophagectomy with lymph adenectomy and were subsequently treated with 5,000 cGy of radiation (days 1-40) and concurrently with two courses of chemotherapy (cisplatin, vindesine and pepleomycin, days 21-26 and 49-54). Results were compared with those of 26 historical control patients, treated with radiation since 1981. Tolerance in all patients was good. The survival rate at 5 years was significantly improved for the multimodality-treated patients (30.9 +/- 9.4%), as compared with findings in historical controls (5.1 +/- 4.8%). The concurrent chemoradiation therapy using these three drugs following extensive surgery is worthy of consideration for patients with a localized esophageal cancer.
1986年至1991年间，35例食管癌患者（TNM分期为II - IV期）接受了经胸食管切除术及淋巴结清扫术，随后接受了5000 cGy的放疗（第1 - 40天），并同时接受了两个疗程的化疗（顺铂、长春地辛和平阳霉素，第21 - 26天和第49 - 54天）。将结果与1981年以来接受放疗的26例历史对照患者的结果进行了比较。所有患者的耐受性良好。与历史对照患者（5.1±4.8%）相比，接受多模式治疗的患者5年生存率显著提高（30.9±9.4%）。对于局限性食管癌患者，广泛手术后使用这三种药物进行同步放化疗值得考虑。
